Cheetah Medical Announces Supplier Agreement with Allina Health
NEWTON, Mass.–(BUSINESS WIRE)–Cheetah Medical has signed a supplier contract with Allina Health, a leading non-for-profit healthcare system serving communities throughout Minnesota and western Wisconsin. The contract enables Allina Health facilities to have access to Cheetah Medical’s hemodynamic monitoring solutions to guide volume management decisions in septic patients across the Allina Health hospital network. “Intravenous fluid requirements vary significantly between patients based on underlying health conditions, and it can be a
TELA Bio Announces Commercial Launch of OviTex™ Reinforced BioScaffolds for Ventral Hernia Repair and Abdominal Wall Reconstruction
MALVERN, Pa., July 13, 2016 /PRNewswire/ — TELA Bio, Inc., a surgical reconstruction company leading the development of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the commercial launch of the company’s OviTex™ portfolio of products for use in ventral hernia repair and abdominal wall reconstruction following U.S. Food and Drug Administration (FDA) 510(K) clearance. OviTex RBSs feature an embedded polymer and an intact extracellular matrix (ECM), a biologic building
HighCape Partners and Tissue Banks International Partner to Create Cutting Edge Regenerative Medicine Company Aziyo Biologics
BALTIMORE, Maryland, November 5, 2015 – HighCape Partners, a growth equity fund focused on investing in commercial-stage life sciences companies, today announced it led the formation of and holds a majority interest in newly formed regenerative medicine company,
HighCape Partners Closes Initial $80 Million Growth Equity Fund
BALTIMORE, Maryland, September 16, 2015 – HighCape Partners Management, L.P. today announced the final closing of HighCape Partners, L.P., its initial $80 million growth equity fund focused on investing in commercial-stage life sciences companies.
Cheetah Medical Secures $5 Million Investment from HighCape Partners
Cheetah Medical, Inc., a leader in non-invasive hemodynamic monitoring systems, announced that it has secured an initial investment of $5 million from HighCape Partners, a firm co-founded by Kevin Rakin, who joined Cheetah Medical’s Board of Directors in 2013.
Cheetah Medical appoints Massachusetts General Hospital physician, Douglas M. Hansell, MD, MPH, as Chief Physician Executive
Cheetah Medical has appointed Douglas M. Hansell, MD, MPH, Assistant Clinical Professor of Anesthesia at Massachusetts General Hospital, as Chief Physician Executive.
Study* Shows $3+ of Costs Can Be Avoided by Hospitals for Every $1 They Spend During Surgery by Using Noninvasive Hemodynamic Monitoring
Cheetah Medical announced that a study by Duke University physicians, presented in a poster session at the recent ASA annual meeting, concluded that more than $3 of costs can be avoided by hospitals for every $1 they spend during surgery by using noninvasive hemodynamic monitoring.
Cheetah Medical Expands Product Line, Introduces “Starling™ SV” Noninvasive Hemodynamic Monitoring System
Cheetah Medical has expanded its product line and is now offering the FDA-cleared and CE-marked Starling™ SV—a noninvasive hemodynamic monitoring system that provides data for real-time clinical decision-making and optimized patient outcomes across a hospital’s continuum of care.
Cheetah Medical says its growth is outpacing global market for hemodynamic monitoring systems, expected to reach $1.1 billion by 2019, according to market research firm MarketsandMarkets
Cheetah Medical announced that its growth is outpacing the global hemodynamic monitoring systems market, which is expected to reach $1.1074 billion by 2019 at a CAGR of 4.5% during the forecast period, according to MarketsandMarkets.